Hemophilia A Drugs Market Analysis

  • Report ID: 2422
  • Published Date: Oct 09, 2024
  • Report Format: PDF, PPT

Hemophilia A Drugs Market Analysis

The market is segmented by product, by route of administration, by distribution channel and by region, out of which, the product segment is further segmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, antifibrinolytics, desmopressin and others. The segment for plasma derived coagulation factors is anticipated to hold the largest share in the hemophilia A treatment market on account of highest usage as compared with other products. Plasma derives coagulation factors further can be segmented into factors such as factor VIII, factor IX, factor XIII, von Willebrand factor and active prothrombin complex concentrates. As a result of this, the segment accounts for the highest share in the market. The segment for route of administration is further segmented into intravenous, oral, nasal and others, out of which, the intravenous segment currently holds the largest share in the market. Since the majority of hemophilia A treatment are in the form of injectable drugs, the market share of this route of administration is high. Moreover, administration of the drug directly into the blood is preferred over other routes. The segment for distribution channel is segmented into hospital pharmacy, retail pharmacy and online pharmacy. The segment for retail pharmacy is predicted to hold the leading share in the market as a result of growing preference of people for buying medicines are the pharmacies near their homes. On the other hand, the online pharmacy segment is anticipated to witness the highest growth rate on account of increasing demand of buying products online as ease of convenience of buying medications through online portals and having them delivered at home.

Our in-depth analysis of the global market includes the following segments:

By Product

  • Plasma Derived Coagulation Factor Concentrate
  • Recombinant Coagulation Factor Concentrates
  • Antifibrinolytics
  • Desmopressin 
  • Others

By Route of Administration

  • Intravenous
  • Oral
  • Nasal
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2422
  • Published Date: Oct 09, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising cases of hemophilia A and growing awareness among people about the requirement for effective drugs for treatment are major factors driving the market growth.

The market is anticipated to attain a significant CAGR over the forecast period, i.e. 2020-2028.

Asia Pacific is estimated to provide more business opportunities for growth as a result of rising number of patients with hemophilia A and growing awareness about the need for preventing and treating hemophilia.

The major players in the market are Pfizer Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Genzyme Corporation, Grifols, S.A., CSL Behring, Octapharma AG, Aptevo Therapeutics and Ferring Pharmaceuticals.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample